X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vorapaxar (238) 238
index medicus (187) 187
humans (148) 148
clopidogrel (97) 97
cardiac & cardiovascular systems (87) 87
aspirin (76) 76
thrombin (68) 68
acute coronary syndromes (65) 65
secondary prevention (63) 63
male (62) 62
platelet aggregation inhibitors - therapeutic use (60) 60
receptor, par-1 - antagonists & inhibitors (58) 58
female (57) 57
pharmacology & pharmacy (49) 49
middle aged (48) 48
pyridines - therapeutic use (46) 46
ticagrelor (45) 45
lactones - therapeutic use (44) 44
prevention (40) 40
prasugrel (39) 39
treatment outcome (39) 39
risk factors (38) 38
sch 530348 (38) 38
aged (37) 37
antiplatelet therapy (36) 36
lactones - adverse effects (36) 36
pyridines - adverse effects (36) 36
acute coronary syndrome (35) 35
myocardial-infarction (35) 35
peripheral vascular disease (35) 35
platelet aggregation inhibitors - adverse effects (34) 34
stroke (33) 33
animals (32) 32
myocardial infarction (31) 31
thrombosis (31) 31
hematology (30) 30
double-blind (28) 28
safety (28) 28
blood platelets - drug effects (27) 27
clinical trials (27) 27
outcomes (26) 26
pyridines - pharmacology (26) 26
risk (26) 26
coronary heart disease (25) 25
mortality (25) 25
platelet aggregation inhibitors - pharmacology (25) 25
abridged index medicus (24) 24
acute coronary syndrome - drug therapy (24) 24
bleeding (24) 24
blood platelets (24) 24
disease (24) 24
lactones - pharmacology (24) 24
percutaneous coronary intervention (24) 24
thrombin-receptor antagonist (24) 24
blood platelets - metabolism (23) 23
hemorrhage - chemically induced (23) 23
pyridines - administration & dosage (23) 23
lactones - administration & dosage (22) 22
rivaroxaban (22) 22
antagonist vorapaxar (21) 21
cangrelor (21) 21
cardiology (21) 21
ischemia (21) 21
pharmacokinetics (21) 21
atherosclerosis (20) 20
care and treatment (20) 20
protease-activated receptors (20) 20
platelet aggregation inhibitors - administration & dosage (19) 19
platelets (19) 19
receptors, thrombin - antagonists & inhibitors (19) 19
analysis (18) 18
coronary artery disease (18) 18
heart attacks (18) 18
pharmacodynamics (17) 17
platelet aggregation - drug effects (17) 17
protease-activated receptor-1 (17) 17
receptor, par-1 - metabolism (17) 17
stroke - prevention & control (17) 17
therapy (17) 17
atopaxar (16) 16
cardiovascular (16) 16
drug therapy, combination (16) 16
platelet inhibition (16) 16
risk assessment (16) 16
ticlopidine - analogs & derivatives (16) 16
cardiovascular disease (15) 15
dual antiplatelet therapy (15) 15
myocardial infarction - drug therapy (15) 15
platelet activation - drug effects (15) 15
pyridines - pharmacokinetics (15) 15
randomized controlled trials as topic (15) 15
thrombosis - prevention & control (15) 15
adult (14) 14
antiplatelet (14) 14
cardiac patients (14) 14
chemistry, medicinal (14) 14
discovery (14) 14
lactones - pharmacokinetics (14) 14
par-1 antagonist (14) 14
patients (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (249) 249
German (6) 6
Czech (1) 1
French (1) 1
Japanese (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Expert Review of Vaccines, ISSN 1476-0584, 05/2019, Volume 18, Issue 5, pp. 419 - 421
Journal Article
Science translational medicine, ISSN 1946-6242, 2017, Volume 9, Issue 371, p. eaaf5294
Antiplatelet agents are proven efficacious treatments for cardiovascular and cerebrovascular diseases. However, the existing drugs are compromised by unwanted... 
MEDICINE, RESEARCH & EXPERIMENTAL | CELLS | POTENT | CLOPIDOGREL | INHIBITION | PLATELET-AGGREGATION | KINETICS | THROMBIN-RECEPTOR | ANTAGONIST VORAPAXAR | P2Y RECEPTOR | DISCOVERY | CELL BIOLOGY
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 02/2018, Volume 38, Issue 2, pp. 287 - 289
Journal Article
European heart journal, ISSN 0195-668X, 2016, Volume 37, Issue 3, pp. 267 - +
Cangrelor | Angioplasty | Anticoagulation | Bivalirudin | Nitrates | Rhythm monitoring | Dabigatran | Platelet inhibition | Stent | European society of cardiology | Guidelines | Recommendations | Rivaroxaban | Vorapaxar | Apixaban | Fondaparinux | Ticagrelor | Revascularization | Aspirin | Acute cardiac care | Unstable angina | Enoxaparin | Myocardial ischaemia | Beta-blockers | High-sensitivity troponin | Statin | Atherothrombosis | Glycoprotein IIb/IIIa inhibitors | Prasugrel | Early invasive strategy | Clopidogrel | Non-ST-elevation myocardial infarction | Bypass surgery | Chest pain unit | Diabetes | Heparin | Acute coronary syndromes | CARDIAC & CARDIOVASCULAR SYSTEMS | AMERICAN-HEART-ASSOCIATION | MOLECULAR-WEIGHT HEPARIN | ACUTE MYOCARDIAL-INFARCTION | ARTERY-BYPASS SURGERY | DUAL-ANTIPLATELET THERAPY | BARE-METAL STENTS | ACUTE CHEST-PAIN | European Society of Cardiology | SENSITIVITY CARDIAC TROPONIN | DRUG-ELUTING STENTS | Biomarkers - metabolism | Risk Assessment - methods | Diagnosis, Differential | Physical Examination - methods | Humans | Anticoagulants - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Angina Pectoris - etiology | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Cardiotonic Agents - therapeutic use | Algorithms | Coronary Angiography - methods | Percutaneous Coronary Intervention - methods | Acute Coronary Syndrome - diagnosis | Electrocardiography | Non-ST Elevated Myocardial Infarction - therapy | Acute Coronary Syndrome - therapy | Platelet Aggregation Inhibitors - therapeutic use | Non-ST Elevated Myocardial Infarction - diagnosis | Purinergic P2Y Receptor Antagonists - therapeutic use | Anticoagulants | Risk Assessment | Angina Pectoris | Platelet Glycoprotein GPIIb-IIIa Complex | Hemorrhage | Cardiotonic Agents | Life Sciences | Coronary Angiography | Human health and pathology | Non-ST Elevated Myocardial Infarction | Platelet Aggregation Inhibitors | Biomarkers | Physical Examination | Purinergic P2Y Receptor Antagonists | Percutaneous Coronary Intervention | Cardiology and cardiovascular system | Acute Coronary Syndrome
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 15, pp. 1404 - 1413
Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of... 
ATOPAXAR | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | EFFICACY | SAFETY | TOLERABILITY | DOUBLE-BLIND | PRASUGREL | LESSONS | ANTAGONISTS | ASPIRIN | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Peripheral Arterial Disease - drug therapy | Stroke - drug therapy | Lactones - adverse effects | Lactones - therapeutic use | Retreatment | Myocardial Infarction - drug therapy | Brain Ischemia - drug therapy | Intracranial Hemorrhages - chemically induced | Intracranial Hemorrhages - epidemiology | Aged | Hemorrhage - chemically induced | Prevention | Drugs | Aggregation | Dose-response relationship (Biochemistry) | Atheroembolism | Blood platelets | Atherosclerosis | Product/Service Evaluations | Dosage and administration | Drug therapy | Myocardial infarction | Cerebral infarction | Stroke | Aspirin | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Hemorrhage | Patients | Bleeding | Disease prevention | Ischemia | Arteriosclerosis | Death | Cardiovascular diseases | Health risk assessment | Computer Science | Medical Imaging
Journal Article
ACS Medicinal Chemistry Letters, ISSN 1948-5875, 05/2014, Volume 5, Issue 5, pp. 561 - 565
We have synthesized several C7-spirocyclic analogues of vorapaxar and evaluated their in vitro activities against PAR-1 receptor. Some of these analogues... 
himbacine | PAR-1 antagonist | vorapaxar | thrombin receptor
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 31, pp. 21655 - 21662
Background: Twenty years after the onset of diabetes, up to 40% of patients develop diabetic nephropathy. Protease-activated receptor-1 (PAR-1) has recently... 
Mesangial expansion | Pathology | Diabetic nephropathy | Vorapaxar | Protease-activated receptor-1 | Streptozotocin
Journal Article
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 8, pp. 911 - 921
Journal Article